Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 9, 2013, Pages 2092-2098

  Hombach, Michael ^a   Mouttet, Brice ^a   Bloemberg, Guido V ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

AST; Carbapenems; Cephalosporins; Penicillins

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAMASE AMPC; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DISK DIFFUSION; ENTEROBACTERIACEAE; GENOTYPE; NONHUMAN; PRACTICE GUIDELINE;

AST; CARBAPENEMS; CEPHALOSPORINS; PENICILLINS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PRACTICE GUIDELINES AS TOPIC;

EID: 84882729392     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt136     Document Type: Article

References (31)

1. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008; 13: pii 1/4 19044.
2. Rodriguez-Villalobos H, Bogaerts P, Berhin C et al. Trends in production of extended-spectrum β-lactamases among Enterobacteriaceae of clinical interest: results of a nationwide survey in Belgian hospitals. J Antimicrob Chemother 2011; 66: 37-47.
3. Pitout JD. Infections with extended-spectrum β-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010; 70: 313-33.
4. Schwaber MJ, Navon-Venezia S, Kaye KS et al. Clinical and economic impact of bacteremia with extended-spectrum- β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50: 1257-62.
5. Tumbarello M, Sanguinetti M, Montuori E et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrumb- lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007; 51: 1987-94.
6. Park YS, Yoo S, Seo MR et al. Risk factors and clinical features of infections caused by plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae. Int J Antimicrob Agents 2009; 34: 38-43.
7. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-86.
8. Pitout JD, Hanson ND, Church DL et al. Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum blactamases: importance of community isolates with blaCTX-M genes. Clin Infect Dis 2004; 38: 1736-41.
9. Rodriguez-Bano J, Navarro MD, Romero L et al. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43: 1407-14.
10. Jacoby GA. AmpC β-lactamases. Clin Microbiol Rev 2009; 22: 161-82.
11. Mulvey MR, Bryce E, Boyd DA et al. Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob Agents Chemother 2005; 49: 358-65.
12. Peter-GetzlaffS, Polsfuss S, Poledica M et al. Detection of AmpC β-lactamase in Escherichia coli: comparison of three phenotypic confirmation assays and genetic analysis. J Clin Microbiol; 49: 2924-32.
13. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 3.1. 2013. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_3.1.pdf (8 April 2013, date last accessed).
14. Leclercq R, Canton R, Brown DF et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 2011; 19: 141-60.
15. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100-S19. CLSI, Wayne, PA, USA, 2009.
16. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-third Informational Supplement M100-S23. CLSI, Wayne, PA, USA, 2013.
17. EUCAST. Expert Rules in Antimicrobial Susceptibility Testing. Version 1. 2008. http://www.eucast.org/expert_rules (8 April 2013, date last accessed).
18. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 1.0. 2010. http://www.eucast.org/antimicrobial_ susceptibility_testing/previous_versions_of_tables/(8 April 2013, date last accessed).
19. Polsfuss S, Bloemberg GV, Giger J et al. Evaluation of a diagnostic flow chart for detection and confirmation of extended spectrum blactamases (ESBL) in Enterobacteriaceae. Clin Microbiol Infect 2012; 18: 1194-204.
20. Polsfuss S, Bloemberg GV, Giger J et al. Practical approach for reliable detection of AmpC β-lactamase-producing Enterobacteriaceae. J Clin Microbiol 2011; 49: 2798-803.
21. Moland ES, Hanson ND, Black JA et al. Prevalence of newer β-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002. J Clin Microbiol 2006; 44: 3318-24.
22. Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002; 40: 2153-62.
23. CaroffN, Espaze E, Gautreau D et al. Analysis of the effects of 242 and 232 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing AmpC. J Antimicrob Chemother 2000; 45: 783-8.
24. Wang P, Hu F, Xiong Z et al. Susceptibility of extended-spectrumb- lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints. J Clin Microbiol 2011; 49: 3127-31.
25. Livermore DM, Andrews JM, Hawkey PM et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 2012; 67: 1569-77.
26. Wang P, Hu F, Xiong Z et al. Susceptibility of extended-spectrumb- lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints. J Clin Microbiol 2011; 49: 3127-31.
27. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74.
28. Szabo D, Silveira F, Hujer AM et al. Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae. Antimicrob Agents Chemother 2006; 50: 2833-5.
29. Wang XD, Cai JC, Zhou HW et al. Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid-mediated β-lactamase production and OmpK36 porin deficiency. J Med Microbiol 2009; 58: 1196-202.
30. Woodford N, Dallow JW, Hill RL et al. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 2007; 29: 456-9.
31. Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66.